The Coherus Leadership Team

Dennis M. Lanfear
President, CEO and Chairman
Industry Experience | 29 years
Prior Experience | Amgen, Baxter

Dennis Lanfear is a pioneer and leader within the biotechnology industry with a track record for entrepreneurial vision and accomplishment. Most recently as the founding President, CEO and Chairman of Coherus BioSciences, he has advanced Coherus from its inception in 2010 into a publically traded organization widely regarded as the leading pure play biosimilar company for the major regulated markets. His vision for improved access to high quality, life-changing medicines has led to the development of a late stage pipeline of biosimilar candidates for the treatment of inflammatory diseases and oncology, strategic collaborations with Daiichi Sankyo and Baxter International , the financial strength of over $220M in private financing, and $81.5M in net proceeds associated with the Company’s Initial Public Offering in November 2014, and the creation of talented organization of leading drug developers.

Mr. Lanfear has nearly 30 years of biopharmaceutical business experience in technical and leadership roles. He is a 13-year veteran of Amgen. where he was a Corporate Officer and Vice President with broad operational, product development and marketing responsibility. His tenure began in 1986 as a founder of the Process Development Department. Under his 10-year leadership, this group became the preeminent process development organization in biopharmaceuticals and a key strategic advantage for the company. As Vice President of Process Development and Operations Systems, he directed the business process integration of more than 2,500 operations and quality staff worldwide.

While at Amgen, he also had senior leadership roles in several product development programs including those for growth factors, somatotropins and neurotrophins, directing efforts from preclinical to Phase 3. He reviewed and wrote sections of more than 20 INDs and several BLAs. He managed corporate partner relationships including that with SKB from 1986 to 1990. He also managed and had direct budgetary responsibility for the $135 million development partnership with Regeneron Pharmaceuticals from 1991 to 1999. In 1997 Mr. Lanfear was named Vice President, Market Development, where he defined long term competitive and reimbursement strategies for Epogen®, a multibillion dollar drug. Prior to joining Amgen, Mr. Lanfear held positions of increasing responsibility at Baxter International.

Mr. Lanfear also was the founder and former CEO of Saronyx, Inc., a drug development software services company with several major biotech clients. In 2005 Mr. Lanfear founded InteKrin Therapeutics and from 2005 to 2010 he was the company’s President and CEO. He became Chairman of the Board in 2010. Under Mr. Lanfear’s five-year leadership a $250 million asset was in-licensed, more than $45 million was raised in venture capital and the company was taken from inception to having a Phase 3 lead product candidate in a major therapeutic area with high market potential.

Mr. Lanfear is an investor in and former Director of Anthera Pharmaceuticals, and a former Director of Insmed Therapeutics, a publicly traded company.

Mr. Lanfear earned degrees in Biochemistry and Chemical Engineering from Michigan State University and earned his MBA from the Anderson School at UCLA.

View Full Bio

Barbara Finck, M.D.
Chief Medical Officer
Industry Experience | 20 years
Prior Experience | Immunex, PDL Biopharma, NKT Therapeutics, Osprey Pharmaceuticals

Dr. Finck is a board certified rheumatologist with over 20 years of preclinical and clinical drug development experience in academic and biopharmaceutical settings in multiple therapeutic areas. She received her rheumatology training at University of California, San Francisco, where she studied the effects of CTLA4-Ig (subsequently developed and marketed as Orencia®) in a murine lupus nephritis model.

She started her pharmaceutical career at ALZA as medical director for early clinical development of Ditropan-XL®. Dr. Finck subsequently has held senior level positions in several biopharmaceutical companies including Immunex (lead medical director for the Phase III clinical development of Enbrel® in Rheumatoid Arthritis and Juvenile Idiopathic Arthritis), Eos Biotechology (VP, Clinical Development) and PDL Biopharma (VP, Clinical Development), Osprey Pharmaceuticals USA, Inc. (Senior VP, Research and Development, and Chief Medical Officer), and NKT Therapeutics, Inc. (Chief Medical Officer).

Throughout her career in pharmaceutical development, she has demonstrated her ability to build effective teams and alliances and her passion for developing therapeutics for diseases that represent a significant unmet medical need.

View Full Bio

Alan Herman, Ph.D.
Chief Scientific Officer
Industry Experience | 32 years
Prior Experience | Genentech, Amgen, Merck, WindRose, Analytica

Dr. Herman has more than 32 years of experience in the biopharmaceutical industry. He started his career at Merck, where he worked on recombinant hepatitis B vaccine. In 1984, he went to Genentech where he worked first in process development and later in pharmaceutics. During his time at Genentech Dr. Herman worked on a number of products, including human growth hormone, tissue plasminogen activator, and interferon.

In 1989 Dr. Herman left Genentech and went to Amgen where he started the Analytical Research and Development Department. During his 11 year leadership this group developed much of the cutting-edge analytics that eventually resulted in a complete reversal of the regulatory view of recombinant products. This new definition of “Well Defined Biological Products” allowed for much more rapid product development and, ultimately, for the entry of biosimilar products to the market. During his tenure at Amgen, his department contributed to over 20 INDs and several BLAs.

In 2003, Dr. Herman went to work as Senior Director of Quality Control for Tercica, Inc., a start-up company which had in-licensed a late-stage compound (IGF-1) from Genentech. His primary responsibility was to design a comparability program that would minimize the need for further clinical trials. Dr. Herman’s additional responsibilities were to engage and supervise contract laboratories for product characterization, method development and validation, release testing, and clinical and commercial stability. IGF-1 received a commercial license within two years of company formation.

In 2005, Dr. Herman founded and served as CEO of WindRose Analytica, Inc., a contract analytical laboratory. He brought the company to profitability within two years and established a client base which included several large international pharmaceutical companies. WindRose Analytica quickly gained a reputation as one of the world’s outstanding protein analytical laboratories. In 2009, WindRose Analytica was acquired by Althea Technologies, Inc., resulting in a positive return to the investors. Dr. Herman served as CSO and Vice President of Product Development at Althea until joining Coherus Biosciences in April of 2011.

Dr. Herman received his B.S. and M.S. degrees in biology at Indiana University of Pennsylvania. He received a Ph.D. in protein chemistry from Duke University, and did his post-doctoral work in oncogenic virus structure at Duke University Medical Center under Dr. Dani Bolognesi.

View Full Bio

Jean-Frederic Viret, Ph.D.
Chief Financial Officer
Prior Experience | diaDexus, Inc., XDx, Inc.

Dr. Viret has served as the Company’s Chief Financial Officer since September 2014. Previously, Dr. Viret was Chief Financial Officer at diaDexus, Inc., a cardiovascular diagnostics company, from February 2012 to September 2014. Prior to that, Dr. Viret was Chief Financial Officer at XDx, Inc. (now CareDx, Inc.), a privately held molecular diagnostics company, from December 2009 to January 2012. From March 2009 to December 2009, Dr. Viret served as the President of JV Consulting, a private consulting firm that provided accounting, public company compliance and other financial consulting services to technology companies.

Prior to that time, Dr. Viret served in various capacities at Anesiva, Inc. (previously known as Corgentech Inc.), a public biopharmaceutical company, most recently as a finance consultant from February 2009 to May 2009. Dr. Viret served as Anesiva’s Vice President and Chief Financial Officer from March 2008 to February 2009 and as its Vice President, Finance from August 2006 to February 2008. Dr. Viret held various positions in finance in Anesiva from December 2002 to August 2006 and at Tularik Inc. from March 2000 to November 2002. He held various positions in the business assurance services of PricewaterhouseCoopers LLP from September 1997 to March 2000. Dr. Viret has served on the board of trustees of the International School of the Peninsula in Palo Alto, California since September 2011, where he is a member of the finance, investment and audit committees. Dr. Viret received a B.S. in Engineering from the Institut National Polytechnique de Lorraine, an M.B.A. from Cornell University and a Ph.D. in Plant Molecular Biology from Université Louis Pasteur (Strasbourg I). He was a visiting fellow at Harvard University and a postdoctoral fellow at the Massachusetts Institute of Technology.

View Full Bio

Peter Watler, Ph.D.
Chief Technical Officer
Industry Experience | 32 years
Prior Experience | Amgen, Hyde, VaxGen

Dr. Watler has over 32 years of biopharmaceutical process development and manufacturing experience, nearly half of which was gained in process development and manufacturing at Amgen. He is highly experienced with the development and scale-up of biopharmaceutical processes including key unit operations such as fermentation, centrifugation, filtration, and chromatography. Dr. Watler brings a strong skillset for process modeling, economic analysis, manufacturing operational excellence, process control and validation. His regulatory experience includes co-authoring two IND submissions, four BLA submissions, and participation in several FDA inspections and GMP audits.

Dr. Watler is a 12-year veteran of Amgen, which he joined in 1990. While at Amgen, he held roles leading process scale-up, manufacturing technical services and pilot plant operations. As Associate Director of Process Engineering, he oversaw the start-up of a 30,000 square foot pilot plant for monoclonal antibody development. In this role he implemented systems to accelerate technology transfer and scale up from the laboratory through to clinical production for over ten product candidates. He also led teams responsible for the process validation of Neupogen®, Stemgen®, Kepivance® and Infergen®.

Dr. Watler most recently served as Chief Technology Officer of Hyde Engineering + Consulting, Inc. He led projects for GMP manufacturing facility design where he employed state-of-the-art technologies to drive down capital costs while enhancing cGMP compliance and operational efficiency. Dr. Watler has presented extensively in the US, Canada, China, Europe and Japan on the latest ICH, FDA and ASTM approaches to pharmaceutical risk management, process validation and Quality by Design.

Dr. Watler was previously Vice President, Manufacturing at VaxGen, a Genenetech spinoff formed to develop an AIDS vaccine. He led the design, construction, and validation of a GMP facility for recombinant vaccine production. This fast-track project featured systems from top tier suppliers and went from design through construction to start-up in just 12 months. Dr. Watler was also responsible for managing supply chain and production operations, led the CMC team and prepared submissions for the FDA, NIH and DHHS. He began his career with Allelix Biopharmaceuticals as a Process Development Engineer optimizing fermentation mass transfer and product harvest operations.

Dr. Watler holds a Bachelor’s and a Master’s degree in Chemical Engineering from the University of Toronto where he developed a prototype implantable insulin pump and a Ph.D. in Chemical Engineering from Yamaguchi University, Japan where he implemented mechanistic modeling techniques for the scale-up and optimization of protein chromatography.

View Full Bio

Vince Anicetti
SVP, Global Quality
Industry Experience | 35 years
Prior Experience | Genentech, Boehringer-Ingelheim

Mr. Anicetti has over 35 years of biopharmaceutical experience and an extensive background developing and leading Biopharmaceutical Quality organizations. Prior to joining Coherus in 2014, he was the Executive Director of Quality for Boehringer-Ingelheim’s California facility. In this role Mr. Anicetti was responsible for Quality, EH&S, and on-site Regulatory Chemistry, Manufacturing, and Control. Prior to joining BI, Vince was a Scientific and Regulatory Affairs Fellow with the Parenteral Drug Association.

Before joining PDA, Mr. Anicetti spent 30 years with Genentech and held senior leadership roles in Quality, Regulatory Affairs and Project Portfolio Management. Mr. Anicetti’s most recent role with Genentech/Roche was Vice President of Biologics Quality with global responsibility for Quality operations at Genentech and Roche Biologics manufacturing sites, maintaining global quality and compliance for 10 major biotechnology products across 10 drug substance and drug product production facilities around the world.

Mr. Anicetti is also an adjunct professor at the Keck Graduate Institute teaching classes in Biopharmaceutical Quality and CMC Regulatory Affairs. He is a past Chair of the Parenteral Drug Association and serves on the San Francisco State University Foundation Board. Mr. Anicetti holds BA and MS degrees in biological sciences from San Francisco State University.

View Full Bio

Lisa M. Bell, Ph.D.
SVP, Global Regulatory Affairs
Industry Experience | 15 years
Prior Experience | BioMarin, Facet Biotech, Genentech

Dr. Bell joined Coherus in 2014 with more than 15 years of experience in global regulatory affairs and drug development across various therapeutic areas at preeminent biotech companies. Dr. Bell has extensive experience in driving regulatory strategy of large and small molecule programs from pre-clinical through post-marketing phases of development. She has worked across several therapeutic areas, including oncology, neurology/inflammation and rare diseases.

Dr. Bell most recently served as global head of Regulatory, Pharmacovigilance, Medical Writing and Development Quality Assurance at BioMarin Pharmaceutical. During her tenure, she led the department through various regulatory milestones including the regulatory advice process to enable the initiation of three, global Phase 3 programs and the approval in the U.S. and EU of Vimizim for Mucoplysacchardosis IVA, a debilitating and life-limiting rare disease.

Dr. Bell’s previous posts included Senior Director of Regulatory and Safety at Facet Biotech and she is a 10-year veteran of Genentech where she held various positions of increasing responsibility. Among other responsibilities, she led regulatory strategy for the Angiogenesis Franchise, including the regulatory approvals for Avastin in Non-Small Cell Lung Cancer, late stage Colorectal Cancer, Glioblastoma and Renal Cell Cancer. Additionally Lisa has led regulatory staff responsible for programs ranging from pre-clinical stage through post-marketing which included biologics, small molecule and antibody-drug conjugate programs.

Dr. Bell earned her Bachelor’s (Biology) and Masters (Biotechnology) degrees from Boston University and a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley.

View Full Bio

Michael Fleming
SVP, Commercial Strategy
Industry Experience | 26 years
Prior Experience | Elan Corporation, Genentech, GlaxoSmithKline

Mr. Fleming, an executive biotech professional with more than 26 years of experience in the biopharmaceutical industry, joined Coherus in 2014. He has been instrumental in the launch, commercial and business development of numerous products in various therapeutic areas, including: HIV, infectious diseases, diabetes, CNS conditions, multiple sclerosis, cardiovascular and oncology. Mr. Fleming has held senior leadership or executive management team roles at several companies including Elan Corporation, Nuvelo, Inc., Genentech, GlaxoSmithKline, SmithKline Beecham and inVentiv Health.

At Elan Corporation plc., Mr. Fleming was Senior Vice President of Commercial and Tysabri Brand with responsibility for leading the commercial organization and Elan’s efforts in the global commercial Tysabri collaboration with Biogen Idec. Prior to that role, he spent several years as a management consultant at inVentiv Health Consulting (Campbell Alliance), heading up their Western US Biotech Corporate Development Practice. Before joining inVentiv Health, Mr. Fleming was Vice President, Commercial Operations at Nuvelo, Inc. as well as Head of Hematology Marketing at Genentech where he was responsible for overseeing the U.S. Rituxan hematology/oncology commercial effort. At GlaxoSmithKline, he was the worldwide commercial strategy lead for Zofran & Supportive Care. Mr. Fleming has also held executive positions at GlaxoSmithKline Canada and its predecessor companies, including Vice President, HIV Oncology Vaccines Business Unit and Vice President, Healthcare Policy and Market Access. In this role, in addition to leading a lobbyist unit, he was responsible for developing commercial reimbursement and health economics strategy for the organization.

Mr. Fleming earned a Microbiology Specialist Degree (BSc) at Victoria College, University of Toronto, and an MBA at the Rotman School of Business, University of Toronto.

View Full Bio

Matthew R. Hooper
SVP, General Counsel
Industry Experience | 26 years
Prior Experience | Johnson & Johnson, Amoco, Abbott Laboratories

Mr. Hooper joined Coherus in October 2012 as Vice President, Legal Affairs. In September 2013, he was promoted to Senior Vice President and General Counsel with responsibility for managing the company’s legal affairs worldwide. Before joining Coherus, Mr. Hooper was Of Counsel with the Life Sciences Group of Wood, Phillips, Katz, Clark and Mortimer in Chicago, where Coherus was one of his principal clients.

Prior to Wood Phillips, Mr. Hooper served as Vice President and General Counsel for Halozyme Therapeutics, and before that, he served in the legal departments of Scios, Inc. and its parent company, Johnson & Johnson from 2000-2006. His roles with Scios and J&J included Senior Patent Counsel and General Counsel for Scios (at the time of J&J’s acquisition of Scios), as well as Assistant General Counsel for J&J. Mr. Hooper has also held positions of increasing responsibility in the corporate law departments of Amoco (later British Petroleum) and Abbott Laboratories.

Matt earned his law degree from Northwestern and his undergraduate degree in Chemistry from LaSalle University in Philadelphia. He is admitted to the bar in Illinois and California and is registered to practice before the U.S. Patent and Trademark office.

View Full Bio

Aaron Schuchart
SVP, Business Development
Industry Experience | 25 years
Prior Experience | Novartis/Grifols, Proaltus Partners, Amgen

Aaron Schuchart is a strategic and transaction-oriented life sciences executive with a proven track record in successfully building and operating new ventures in large multi-national corporations and small start-ups. Most recently, he was Head of Business Development and Strategic Planning for Grifols/Novartis Diagnostics where he led the development of the combined companies’ strategic plan. Previously, he was Managing Director of Proaltus Partners, LLC, a life sciences advisory firm, where he led a broad range of business development, capital formation, and strategic planning projects for small to mid-size clients. He also held senior business development, strategy, and financial management positions at Mendel Biotechnology, Amgen, and Arco. He has closed over 30 licensing and strategic partnership transactions in excess of $1B. Mr. Schuchart has contributed to numerous publications and presentations as both an advisor and speaker at industry conferences.

Mr. Schuchart has a BS from Texas Tech University, an MBA from the Anderson School at UCLA, is a CPA and a Certified Licensing Professional (CLP).

View Full Bio